Director Magda Marquet granted options and RSUs at First Tracks (TRAX)
Rhea-AI Filing Summary
First Tracks Biotherapeutics director Magda Marquet received new equity awards as part of her compensation. She was granted options to buy 42,000 shares of common stock at an exercise price of $17.81 per share, expiring on May 11, 2036. These options vest monthly, with 1/12 of the total vesting each month starting on June 12, 2026, as long as she continues serving the company.
She also received 15,000 restricted stock units, each representing the right to receive one share of common stock for no cash payment. All of these RSUs vest on the date of First Tracks’ 2027 annual meeting of shareholders, subject to her continued service. In addition to this new option grant, she already holds options to purchase up to 70,104 shares of common stock that vest according to their existing terms.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 15,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 42,000 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. In addition to the options to purchase a total of 42,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms.